Effect of Bosweilia serrata in prevention of cognitive impairment progression in multiple sclerosis

Comparesion between treatment with Bosweilia serrata against placebo to change the progression of cognitive disorders in Multiple sclerosis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013070813911N1

Enrollment

Registered

2013-08-22

Start date

2013-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: cap Bosweilia serrata 300mg BD. 2 months for intervention group. Intervention 2: Cap placebo 300mg BD ,2 months for control group.

Treatment - Drugs

Placebo

cap Bosweilia serrata 300mg BD. 2 months for intervention group

Cap placebo 300mg BD ,2 months for control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criterion: definite multiple sclerosis. Exclusion criteria: taking new drugs; hypersensitivity to Bosweilia serrata and drug side effect.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cognitive impairment. Timepoint: Befor intervention and 2month later. Method of measurement: BICAMS TEST.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnaz Sedighi

Shafa hospital, Kerman University of Medical Sciences

Behnaz.sedighi@gmail.com+98 34 1211 5780

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026